Recent Episodes

Young patients with breast cancer should always aim to advocate for themselves, said Shari Goldfarb, MD.

Experts discussed the critical intersection of oncology and mental health, which included identifying and mitigating suicide risk factors.

Experts discuss the evolution of rectal cancer care from the use of “cookie cutter” approaches to the growth of personalized treatment pathways.

Julian Hong, MD, MS, offered strategies for providing mental health services to routine workflows for patients undergoing anticancer treatment.

Experts detail presentations that may influence the standard of care across different bladder, kidney, and prostate cancer populations.

Looking ahead, local therapies and biomarkers may become even more important in the management of kidney cancer.

Experts explore the complexities of cannabis use, the financial impact, and best practices for administration in patients with cancer.

Experts from Columbia University highlight approvals in CLL, bispecific antibodies in multiple myeloma, and actionable biomarkers in DLBCL.

Host Brandon Mancini, MD, MBA, FACRO, discusses presentations from ASCO GU 2026 featuring potential advances in the use of radiotherapeutic regimens.

Daniel C. McFarland, DO, and Boris Kiselev, MD, highlight the need for oncologists to recognize and address depression for patients with cancer.

Experts review strategies for effective screening and other measures for limiting cancer incidence in observance of National Cancer Prevention Month.

Experts review potential clinical advances highlighted at the 2026 ASCO Gastrointestinal Cancers Symposium.

Experts discuss how issues related to prostate cancer diagnoses and access to care differ across practices based in the US and India.

Researchers and clinicians share key updates in leukemia, lymphoma, and myelodysplastic syndrome that they presented at the 2026 Tandem Meetings.

Experts outline current initiatives from the American College of Radiation Oncology as well as potential next steps for advancing the field.

Experts discuss new modalities such as HPV vaccines, balancing hope with realism, and other considerations in cervical cancer management.

Nathan Goodyear, MD, discussed key insights in integrative oncology care as well as evidence-based, patient-centric tools that may optimize QOL outcomes.

Experts cover the regulatory approvals and clinical trial readouts from 2025 that may move the needle for prostate cancer management.

Host Brandon Mancini, MD, MBA, FACRO, introduces a special podcast series focused on delivering key insights and takeaways in the radiation oncology space.

Opening dialogue and establishing connections across different oncology camps may enhance the use of integrative modalities and bolster patient outcomes.

Experts break down the clinical trial data and regulatory developments that made 2025 a “remarkable year” in kidney and bladder cancer management.

Jose G. Trevino II, MD, FACS, emphasized educating patients and physicians alike to help recognize early signs of pancreatic ductal adenocarcinoma.

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

Experts discussed supportive care and why it should be integrated into standard oncology care.

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.